Uptravi and Weight loss - a phase IV clinical study of FDA data

Summary:

Weight loss is reported as a side effect among people who take Uptravi (selexipag), especially for people who are female, 60+ old, also take Letairis, and have Primary pulmonary hypertension.

The phase IV clinical study analyzes which people have Weight loss when taking Uptravi. It is created by eHealthMe based on reports of 26,571 people who have side effects when taking Uptravi from the FDA, and is updated regularly.

What is Uptravi?

Uptravi has active ingredients of selexipag. eHealthMe is studying from 26,576 Uptravi users. Check the latest studies of Uptravi.

What is Weight loss?

Weight loss is found to be associated with 1,449 drugs and 2,293 conditions by eHealthMe. Check the latest studies of Weight loss.

On Jul, 15, 2026

26,571 people reported to have side effects when taking Uptravi.
Among them, 12 people (0.05%) have Weight loss.

Among these 12 people:

What is the gender of people who have Weight loss when taking Uptravi? *

female: 100 %
male: 0.0 %

What is the age of people who have Weight loss when taking Uptravi? *

What are other drugs people take besides Uptravi? *

What are other side effects people have besides Weight loss? *

Dyspnea (difficult or laboured breathing): 9 people, 75.00%
Headache (pain in head): 8 people, 66.67%
Muscle Aches (muscle pain): 7 people, 58.33%
Pain In Extremity: 7 people, 58.33%
Pain: 6 people, 50.00%
Nasal Congestion (blockage of the nasal passages usually due to membranes lining the nose becoming swollen from inflamed blood vessels): 6 people, 50.00%
Stress And Anxiety: 6 people, 50.00%
Diarrhea: 6 people, 50.00%
Malaise (a feeling of general discomfort or uneasiness): 6 people, 50.00%
Nausea (feeling of having an urge to vomit): 5 people, 41.67%

What are the existing conditions these people have? *

Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 10 people, 83.33%
Urinary Tract Infection: 4 people, 33.33%
Rhinitis Perennial (an inflammatory condition of the nose characterized by nasal obstruction, sneezing, itching): 1 person, 8.33%
Respiratory Disorder (respiratory disease): 1 person, 8.33%
Oropharyngeal Candidiasis (fungal infection of oropharynx): 1 person, 8.33%
Oedema (fluid collection in tissue): 1 person, 8.33%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 1 person, 8.33%
High Blood Pressure: 1 person, 8.33%
Dry Eyes (lack of adequate tears): 1 person, 8.33%
Diarrhea: 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Uptravi and have Weight loss?

- Check whether Weight loss is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Uptravi:

Uptravi (26,576 reports)

Weight loss treatments and more:

Weight loss (62,430 reports)

Browse all side effects of Uptravi:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Weight loss:

Weight loss (1,449 drugs)

Browse all the conditions that are associated with Weight loss:

Weight loss (2,293 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on selexipag (the active ingredients of Uptravi) and Uptravi (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.